Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
2023 stock pick: GSK is cheap versus peers and is finally going places

Many healthcare stocks did well on the stock market in 2022, yet one company stood out as a laggard due to a legal matter which has just seen an important breakthrough.
GSK (GSK) fell 10% in the year versus a 34% gain both from AstraZeneca (AZN) and Eli Lilly (LLY:NYSE), and a 48% advance from Indivior (INDV).
Holding the FTSE 100 company’s shares back has been litigation pursued in US courts over claims that GSK’s heartburn drug Zantac caused cancer.
In early December, one class action suit representing thousands of claimants was dismissed by a US federal judge on the basis it lacked scientific evidence. GSK’s shares surged on the news as investors breathed a sigh of relief.
Analysts at Jefferies had estimated a worst-case scenario for GSK leading to compensation payments of up to $17 billion with some estimates from other analysts as high as $45 billion.
An appeal is still possible from the claimants regarding the dismissed Zantac case and there are associated cases still outstanding. Therefore, anyone buying the shares must understand the risks involved with this matter and on a broader basis given there is no guarantee that new drug developments will be successful.
So why should you buy the shares? GSK makes vaccines and specialty medicines to prevent and treat disease. In November the company raised its annual profit and sales guidance for the second time in six months, implying positive momentum in the business.
You’re able to buy the shares far cheaper than most of its quoted peers, so there is the opportunity to get a good entry point if you have faith in the long-term ability for GSK to generate good returns.
GSK currently trades on 9.9 times forecast earnings for 2023. That compares with typical mid-to-high teens ratings for pharmaceutical peers and 13.7 times earnings for the FTSE 100 index. GSK’s shares also offer a 4% prospective dividend yield.
Berenberg believes GSK is on track to deliver double-digit medium-term profit growth with potential for margin expansion.
Activist fund manager Elliott Advisors holds a stake in GSK with the hope of driving change, saying the business is not performing to its potential. GSK has already acquiesced to some of Elliott’s demands including beefing up its board and demerging its consumer healthcare unit, Haleon (HLN).
GSK has since laid out plans to grow sales by more than 5% a year and adjusted operating profit by more than 10% a year between 2021 and 2026.
Important information:
These articles are provided by Shares magazine which is published by AJ Bell Media, a part of AJ Bell. Shares is not written by AJ Bell.
Shares is provided for your general information and use and is not a personal recommendation to invest. It is not intended to be relied upon by you in making or not making any investment decisions. The investments referred to in these articles will not be suitable for all investors. If in doubt please seek appropriate independent financial advice.
Investors acting on the information in these articles do so at their own risk and AJ Bell Media and its staff do not accept liability for losses suffered by investors as a result of their investment decisions.
Issue contents
Feature
- Cerillion’s share price is up 729% in five years: here’s why
- Tate & Lyle, London Stock Exchange and Jet2 shine in our 2022 stock picks
- How it went wrong for Amazon and what comes next
- Greggs: we reveal the secrets of its success and plans for the future
- The story behind the month’s big earnings upgrades
- The reasons why fund managers changed their mind on certain stocks in 2022
- Emerging markets: Views from the experts
- Revealed: the best and worst performing emerging markets in 2022
Great Ideas
- 2023 stock pick: JD Sports Fashion – a great business at the wrong price
- 2023 stock pick: Apple’s shares have become cheaper and it remains a cash-generating giant
- 2023 stock pick: GSK is cheap versus peers and is finally going places
- 2023 stock pick: It could be gold’s year and miner Shanta is a great way to play it
- 2023 stock pick: Premier Foods is looking tasty thanks to booming cake and sauce sales
- 2023 stock pick: Compass is an outsourcing winner with underappreciated growth potential
- 2023 stock pick: ME Group is a resilient, high quality business
- 2023 stock pick: Prudential could be the low-risk way to play China’s reopening
- 2023 stock pick: Walt Disney is ready for a big comeback under Bob Iger
- 2023 stock pick: ASML is set for bumper revenue and earnings growth
News
- Luxury firm Lanvin looks unloved as shares fall 28.5% following market debut
- Ukraine and rates: why the market’s two big bugbears are not going anywhere
- Why Marlowe shares have collapsed despite strong half-year results
- Why Victorian Plumbing shares have rallied 120% in three months
- Could the tobacco industry become extinct after radical new legislation?
- Games Workshop shares hit 11-month high on Amazon licensing deal